世界のインテグリンベータ1治療薬市場パイプラインレビュー(2019年下半期)

Global Markets Directが発行した調査報告書(GDATA20MY0453)
◆英語タイトル:Integrin Beta 1 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0453
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:65
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥728,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,092,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Integrin Beta 1 – Pipeline Review, H2 2019
Summary

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Oncology, Ophthalmology, Immunology, Cardiovascular, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Primary Sclerosing Cholangitis, Liver Fibrosis, Rheumatoid Arthritis, Wet (Neovascular / Exudative) Macular Degeneration, Arterial Thrombosis, Breast Cancer, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fibrosis, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Metastatic Lung Cancer, Metastatic Melanoma, Non-Alcoholic Steatohepatitis (NASH), Prostate Cancer, Solid Tumor and Triple-Negative Breast Cancer (TNBC).

The latest report Integrin Beta 1 – Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
- The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Overview
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Companies Involved in Therapeutics Development
7 Hills Pharma LLC
AsclepiX Therapeutics Inc
Avipero Ltd
AxeroVision Inc
Bausch Health Companies Inc
Morphic Holding Inc
Nodus Therapeutics Inc
ODIN Biotech Partners LLC
Pliant Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Drug Profiles
7HP-349 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody + Small Molecule – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-159 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXT-108 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-16Y – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOD-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1177 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1474 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1561 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-74809 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize Alpha5Beta1 Integrin and EGFR for Triple Negative Breast Cancer and Metastatic Lung Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-300 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha V and Integrin Beta 1 for Fibrosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Dormant Products
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Discontinued Products
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019
Oct 15, 2019: Pliant Therapeutics announces publication demonstrating feasibility of positron emission tomography (PET) tracers for imaging fibrosis in patients with idiopathic pulmonary fibrosis
Jun 28, 2019: Pliant Therapeutics completes trial of PLN-74809 to treat in IPF
Jun 27, 2019: Pliant Therapeutics reports positive results of phase 1b clinical study supporting advancement of PLN-74809 for treatment of Idiopathic Pulmonary Fibrosis
Apr 09, 2019: Pliant Therapeutics reports positive results of phase 1 clinical study support advancement of PLN-74809 for idiopathic pulmonary fibrosis
Mar 28, 2019: Pliant Therapeutics presents data in human NASH liver tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)
Jan 03, 2019: Experimental treatment shows promise against triple-negative breast cancer in mouse study
Jan 03, 2019: Pliant Therapeutics initiates phase 1 clinical study of PLN-74809
Nov 20, 2018: Pliant Therapeutics receives FDA orphan drug designation for lead program PLN-74809 in primary sclerosing cholangitis
Nov 09, 2018: Pliant Therapeutics presents preclinical data in PSC at The Liver Meeting 2018
Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Jul 24, 2018: 7 Hills Pharma appoints Lionel D. Lewis as chief medical officer
Jun 26, 2018: 7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
Jun 19, 2018: 7 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by 7 Hills Pharma LLC, H2 2019
Pipeline by AsclepiX Therapeutics Inc, H2 2019
Pipeline by Avipero Ltd, H2 2019
Pipeline by AxeroVision Inc, H2 2019
Pipeline by Bausch Health Companies Inc, H2 2019
Pipeline by Morphic Holding Inc, H2 2019
Pipeline by Nodus Therapeutics Inc, H2 2019
Pipeline by ODIN Biotech Partners LLC, H2 2019
Pipeline by Pliant Therapeutics Inc, H2 2019
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019

【掲載企業】

7 Hills Pharma LLC
AsclepiX Therapeutics Inc
Avipero Ltd
AxeroVision Inc
Bausch Health Companies Inc
Morphic Holding Inc
Nodus Therapeutics Inc
ODIN Biotech Partners LLC
Pliant Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のインテグリンベータ1治療薬市場パイプラインレビュー(2019年下半期)(Integrin Beta 1 - Pipeline Review, H2 2019)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆